These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 5314423)

  • 1. Effects of L-DOPA and structurally related compounds on blood pressure.
    Henning M; Rubenson A
    Acta Pharmacol Toxicol (Copenh); 1970; 28(1):50. PubMed ID: 5314423
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on the mechanism of the L-3,4-dihydroxyphenylalanine-induced decrease in tyrosine hydroxylase activity.
    Dairman W; Udenfriend S
    Mol Pharmacol; 1972 May; 8(3):293-9. PubMed ID: 4402746
    [No Abstract]   [Full Text] [Related]  

  • 3. The depression of sensitivity to noradrenaline caused by L-dopa.
    Eden E; Nasmyth PA
    J Physiol; 1973 Apr; 230(1):7P-8P. PubMed ID: 4702454
    [No Abstract]   [Full Text] [Related]  

  • 4. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.
    Watanabe AM; Parks LC; Kopin IJ
    J Clin Invest; 1971 Jun; 50(6):1322-8. PubMed ID: 5578236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cardiovascular pharmacology of L(--)-dopa: peripheral and central effects.
    Osborne MW; Wenger JJ; Willems W
    J Pharmacol Exp Ther; 1971 Sep; 178(3):517-28. PubMed ID: 5571901
    [No Abstract]   [Full Text] [Related]  

  • 6. Antagonism of the conversion of alpha-methyldopa to an active symphathomimetic by 3-hydroxy-4-bromobenzyloxyamine (NSD 1055) and 3-hydroxybenzyloxyamine (NSD 1024).
    Weber LJ
    Arch Int Pharmacodyn Ther; 1967 Nov; 170(1):124-7. PubMed ID: 6056583
    [No Abstract]   [Full Text] [Related]  

  • 7. Aromatic amino acid decarboxylase inhibitors.
    Porter CC
    Fed Proc; 1971; 30(3):871-6. PubMed ID: 5575298
    [No Abstract]   [Full Text] [Related]  

  • 8. Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors.
    Lotti VJ; Porter CC
    J Pharmacol Exp Ther; 1970 Apr; 172(2):406-15. PubMed ID: 5441162
    [No Abstract]   [Full Text] [Related]  

  • 9. Parkinsonian syndromes. Treatment by association of L-dopa plus decarboxylase inhibitor.
    Gauthier G; Juge O; Birchler A
    Eur Neurol; 1974; 11(3):133-57. PubMed ID: 4839098
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of different dopa decarboxylase inhibitors on the hypotensive response to alpha-methyldopa in rats.
    Henning M
    Br J Pharmacol; 1968 Sep; 34(1):233P-234P. PubMed ID: 5676035
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of pyridoxal phosphate and L-dopapyridoxal phosphate on DOPA decarboxylase activity.
    Tran N
    Experientia; 1972 Sep; 28(9):1021-2. PubMed ID: 4665286
    [No Abstract]   [Full Text] [Related]  

  • 12. Age-dependent depressor effect of L-dopa in dogs with inhibition of extracerebral dopa decarboxylase.
    Wilke WL
    Pediatr Res; 1983 Nov; 17(11):924-5. PubMed ID: 6359046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) mediates release of l-3,4-dihydroxyphenylalanine (l-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study.
    Foster SB; Wrona MZ; Han J; Dryhurst G
    Chem Res Toxicol; 2003 Oct; 16(10):1372-84. PubMed ID: 14565778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake and decarboxylation of L-3,4-dihydroxyphenylalanine in cultured monkey placenta amniotic epithelial cells.
    Elwan MA; Sakuragawa N
    Placenta; 2007; 28(2-3):245-8. PubMed ID: 16580727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of the reserpine-induced suppression of the conditioned avoidance response by L-dopa: correlation of behavioral and biochemical differences in two strains of mice.
    Seiden LS; Peterson DD
    J Pharmacol Exp Ther; 1968 Feb; 159(2):422-8. PubMed ID: 5638661
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].
    Kaufmann W; Butz P; Wiesendanger M
    Dtsch Z Nervenheilkd; 1970; 197(1):85-100. PubMed ID: 5522871
    [No Abstract]   [Full Text] [Related]  

  • 17. Behavior of fluorinated analogs of L-(3,4-dihydroxyphenyl)alanine and L-threo-(3,4-dihydroxyphenyl)serine as substrates for Dopa decarboxylase.
    Borri Voltattorni C; Bertoldi M; Bianconi S; Deng WP; Wong K; Kim I; Herbert B; Kirk KL
    Biochem Biophys Res Commun; 2002 Jul; 295(1):107-11. PubMed ID: 12083775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro inhibition of dopa decarboxylase by 6-alkyl derivatives of 3-(3,4-dihydroxyphenyl)alanine (dopa).
    Morgenstern AP; Nauta WT
    Arzneimittelforschung; 1972 Oct; 22(10):1766-8. PubMed ID: 4677070
    [No Abstract]   [Full Text] [Related]  

  • 19. Changes in baroreflexes induced by L-dopa.
    Calne DB; George CF; Reid JL; Vakil SD
    Br J Pharmacol; 1972 Nov; 46(3):539P. PubMed ID: 4656624
    [No Abstract]   [Full Text] [Related]  

  • 20. L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles.
    Opacka-Juffry J; Brooks DJ
    Mov Disord; 1995 May; 10(3):241-9. PubMed ID: 7651438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.